The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

(2017) H. Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma

(2011) Jiankun Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer

(2011) Uzma Asghar et al.   Clinical Colorectal Cancer

Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature

(2011) M. Pohl et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer

(2010) Kyung A Kwon et al.   BMC CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies

(2008) Rachel Wong et al.   JOURNAL OF CLINICAL ONCOLOGY